156 related articles for article (PubMed ID: 25988279)
1. Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier.
Vyas A; Jain A; Hurkat P; Jain A; Jain SK
Colloids Surf B Biointerfaces; 2015 Jul; 131():155-61. PubMed ID: 25988279
[TBL] [Abstract][Full Text] [Related]
2. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach.
Makwana V; Jain R; Patel K; Nivsarkar M; Joshi A
Int J Pharm; 2015 Nov; 495(1):439-446. PubMed ID: 26367780
[TBL] [Abstract][Full Text] [Related]
3. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation.
Graverini G; Piazzini V; Landucci E; Pantano D; Nardiello P; Casamenti F; Pellegrini-Giampietro DE; Bilia AR; Bergonzi MC
Colloids Surf B Biointerfaces; 2018 Jan; 161():302-313. PubMed ID: 29096375
[TBL] [Abstract][Full Text] [Related]
4. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.
Martins SM; Sarmento B; Nunes C; Lúcio M; Reis S; Ferreira DC
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):488-502. PubMed ID: 23994244
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies.
Dodiya S; Chavhan S; Korde A; Sawant KK
Drug Dev Ind Pharm; 2013 May; 39(5):733-43. PubMed ID: 22690834
[TBL] [Abstract][Full Text] [Related]
6. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Kuo YC; Su FL
Int J Pharm; 2007 Aug; 340(1-2):143-52. PubMed ID: 17418986
[TBL] [Abstract][Full Text] [Related]
7. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
8. The use of solid lipid nanoparticles for sustained drug release.
Attama AA; Umeyor CE
Ther Deliv; 2015; 6(6):669-84. PubMed ID: 26149784
[TBL] [Abstract][Full Text] [Related]
9. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
Sangsen Y; Wiwattanawongsa K; Likhitwitayawuid K; Sritularak B; Wiwattanapatapee R
Colloids Surf B Biointerfaces; 2015 Jul; 131():182-90. PubMed ID: 25988282
[TBL] [Abstract][Full Text] [Related]
10. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier.
Dal Magro R; Ornaghi F; Cambianica I; Beretta S; Re F; Musicanti C; Rigolio R; Donzelli E; Canta A; Ballarini E; Cavaletti G; Gasco P; Sancini G
J Control Release; 2017 Mar; 249():103-110. PubMed ID: 28153761
[TBL] [Abstract][Full Text] [Related]
11. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Swami R; Singh I; Jeengar MK; Naidu VG; Khan W; Sistla R
Int J Pharm; 2015; 486(1-2):287-96. PubMed ID: 25839415
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting.
Singh I; Swami R; Pooja D; Jeengar MK; Khan W; Sistla R
J Drug Target; 2016; 24(3):212-23. PubMed ID: 26219519
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery.
Jose S; Anju SS; Cinu TA; Aleykutty NA; Thomas S; Souto EB
Int J Pharm; 2014 Oct; 474(1-2):6-13. PubMed ID: 25102112
[TBL] [Abstract][Full Text] [Related]
14. Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability.
Gupta S; Kesarla R; Chotai N; Misra A; Omri A
Biomed Res Int; 2017; 2017():5984014. PubMed ID: 28243600
[TBL] [Abstract][Full Text] [Related]
15. Self-reporter shikonin-Act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation.
Eskandani M; Nazemiyeh H
Eur J Pharm Sci; 2014 Aug; 59():49-57. PubMed ID: 24768857
[TBL] [Abstract][Full Text] [Related]
16. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
17. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
Kumar P; Lakshmi YS; Kondapi AK
HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
[TBL] [Abstract][Full Text] [Related]
18. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
19. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
20. Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis.
Devi R; Jain A; Hurkat P; Jain SK
Pharm Res; 2015 Oct; 32(10):3137-48. PubMed ID: 26198415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
